Numis Reports That They Have Upgraded Indivior Plc (LON:INDV) Shares

July 27, 2018 - By Kristin Houston

Indivior PLC (LON:INDV) Logo

Indivior Plc (LON:INDV) Stock Upgrade

In an analyst note revealed to investors on Friday morning, Numis announced that they have decided to upgrade Indivior Plc (LON:INDV) shares to a “Buy”.

Indivior PLC (LON:INDV) Ratings Coverage

Among 5 analysts covering Indivior Plc (LON:INDV), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Indivior Plc has GBX 640 highest and GBX 350 lowest target. GBX 444.60’s average target is 43.37% above currents GBX 310.1 stock price. Indivior Plc had 23 analyst reports since February 15, 2018 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Wednesday, July 25 report. The firm has “Buy” rating given on Wednesday, May 2 by Numis Securities. On Friday, March 23 the stock rating was maintained by RBC Capital Markets with “Outperform”. Numis Securities downgraded the shares of INDV in report on Wednesday, July 11 to “Hold” rating. The firm has “Neutral” rating given on Tuesday, July 17 by Citigroup. Citigroup downgraded Indivior PLC (LON:INDV) rating on Tuesday, May 15. Citigroup has “Neutral” rating and GBX 500 target. The stock of Indivior PLC (LON:INDV) has “Buy” rating given on Friday, March 23 by Numis Securities. The rating was maintained by Jefferies with “Buy” on Monday, April 9. As per Tuesday, June 19, the company rating was maintained by Numis Securities. The stock of Indivior PLC (LON:INDV) earned “Add” rating by Numis Securities on Wednesday, July 25.

The stock increased 1.11% or GBX 3.4 during the last trading session, reaching GBX 310.1. About 905,322 shares traded. Indivior PLC (LON:INDV) has 0.00% since July 27, 2017 and is . It has underperformed by 12.57% the S&P500.

Indivior PLC, together with its subsidiaries, develops, makes, and sells buprenorphine prescription drugs for the treatment of opioid dependence worldwide. The company has market cap of 2.26 billion GBP. The company's product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It has a 34.46 P/E ratio. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.